This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

John Kinross-Wright, MD

JAMA. 1967;200(6):461-464.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Phenothiazines assumed the rank of major chemotherapeutic agents 14 years ago. Throughout these years they have remained the object of controversy concerning their effectiveness, mode of action, toxicity, and method of use. This is perhaps because they have a spectrum of pharmacological activity and a formidable array of side effects unrivaled by any other class of compounds. The introduction of a factor of this complexity into the arena of mental illness, noted for its preponderance of hypothetical beliefs over scientific fact, was bound to produce controversy. Further, it happened at a time when the public conscience was recognizing its shortcomings in regard to the mentally ill. This has made it difficult to know how much of the change in the status of the mentally ill is due to pharmacotherapy and how much to other factors.

The issue is further compounded by the propensity of the phenothiazines to give rise to . . . [Full Text PDF of this Article]

Author Affiliations
From the Houston State Psychiatric Institute and Baylor University College of Medicine, Houston.

Footnotes
Read before the Section on Nervous and Mental Diseases at the 115th annual convention of the American Medical Association, Chicago, June 29, 1966.

Reprint requests to 1300 Moursund Ave, Houston 77025 (Dr. Kinross-Wright).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?